CONFIRMED DEAL PIPELINE
Drug for Periodon66s
• The investee is a UK based and the management team comprised of ex-senior execu + ves from Novar + s Pharmaceu + cals .
• Reposi + oning of an exis + ng drug compound for treatment of a prevalent dental disease and prevent tooth loss .
• Es + mated market size to be about USD2bn currently but growing because of ageing popula + on and greater awareness of good dental health .
• Exit through sale to large pharma aler comple + on of phase 2 trials in two years .
• Expected annual return is over 30 % p . a .